3-烯丙基-4-羟基苯甲醛 | 41052-88-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-烯丙基-4-羟基苯甲醛
• 英文名称: 3-allyl-4-hydroxybenzaldehyde
• 英文别名: 4-hydroxy-3-allylbenzaldehyde；4-hydroxy-3-(2-propen-1-yl)benzaldehyde；4-hydroxy-3-prop-2-enylbenzaldehyde
• CAS: 41052-88-4
• 化学式: C₁₀H₁₀O₂
• mdl: MFCD06290488
• 分子量: 162.188
• InChiKey: HDZJQLIQQWIJBW-UHFFFAOYSA-N

物化性质

• 沸点：
  283.3±28.0 °C(Predicted)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2912499000
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  3-烯丙基-4-羟基苯甲醛 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 [RuHCl(CO)(PPh₃)₃] potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 25.0h， 生成 2H-chromene-6-carbaldehyde
  参考文献：
  名称：

  Ring-closing metathesis for the synthesis of 2H- and 4H-chromenes

  摘要：

  Six 4H-chromenes were synthesized from substituted phenols using vinylstannylation and ring-closing metathesis (RCM) as key steps. In addition, a different approach involving amongst other steps, an aryl allyl isomerization and RCM afforded a set of seven 2H-chromenes from phenolic precursors. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.08.020
• 作为产物：
  描述：

  4-(3-甲基-2-丁烯氧基)苯甲醛 在 N,N-二乙基苯胺 作用下， 反应 20.0h， 以65%的产率得到3-烯丙基-4-羟基苯甲醛
  参考文献：
  名称：

  Synthesis and biological evaluation of allylated and prenylated mono-carbonyl analogs of curcumin as anti-inflammatory agents

  摘要：

  Curcumin has been shown to possess anti-inflammatory activities but has been limited for its low stability and poor bioavailability. We have previously reported four series of 5-carbon linker-containing mono-carbonyl analogs of curcumin (MACs). In continuation of our ongoing research, we designed and synthesized 33 novel allylated or prenylated MACs here, and evaluated their anti-inflammatory effects in RAW 264.7 macrophages. A majority of them effectively inhibited the LPS-induced expression of TNF-alpha and IL-6, especially IL-6. The preliminary SAR and quantitative SAR analysis were conducted. Compound 14q is the most potent analog among them, and exhibits significant protection against LPS-induced death in septic mice. Together, these data present a series of new analogs of curcumin as promising anti-inflammatory agents. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.10.061

文献信息

• A Useful and Environmentally Benign Synthetic Protocol for Dethiolization by Employing Vanadium Pentoxide Catalyzed Oxidation of Ammonium Bromide by Hydrogen Peroxide
  作者：Ejabul Mondal、Gopal Bose、Priti Rani Sahu、Abu T. Khan

  DOI：10.1246/cl.2001.1158

  日期：2001.11

  presence of olefin and aromatic ring as well as other protecting groups to carbonyl compounds by employing V2O5 catalyzed oxidation of ammonium bromide by H2O2 in CH2Cl2–H2O solvent system; mild conditions, high selectivity, good yield, and no side products such as bromination or oxidation are some of the major advantages.

  在 CH2Cl2–H2O 溶剂体系中，V2O5 催化 H2O2 氧化溴化铵，在烯烃和芳环以及其他保护基团的存在下，多种硫缩醛和硫缩酮可以化学选择性地裂解为羰基化合物；温和的条件、高选择性、良好的收率以及无溴化或氧化等副产物是一些主要优点。
• Oxazole derivatives
  申请人：——

  公开号：US20030055265A1

  公开（公告）日：2003-03-20

  The present invention relates to novel oxazole compounds which act as PPAR&agr; and PPAR&ggr; agonists and are accordingly useful for the treatment of diseases modulated by PPAR&agr; and PPAR&ggr; such as diabetes.

  本发明涉及新型噁唑化合物，其作为PPAR&agr;和PPAR&ggr;激动剂，并因此可用于治疗由PPAR&agr;和PPAR&ggr;调节的疾病，如糖尿病。
• [EN] SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS<br/>[FR] DÉRIVÉS DE SPIRO AZÉTIDINE ISOXAZOLE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE SSTR5
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014142363A1

  公开（公告）日：2014-09-18

  Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

  提供一个具有SSTR5拮抗作用的化合物，该化合物由以下公式（1）或其盐表示：其中每个符号的定义与说明书中相同。
• Heterocyclic derivatives
  申请人：Zeneca Limited

  公开号：US05919793A1

  公开（公告）日：1999-07-06

  Compounds of formula (I) wherein R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 14 CR.sup.2 is a double bond; X is selected from --Ch.sub.2 CH.sub.2 --, --C.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --OCH.sub.2, CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S(O).sub.n -- and --S(O).sub.n CH.sub.2 -- (wherein n is 0, 1 or 2); Ar is phenyl which bears one or more substituents independently selected from the groups (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, (1-6C)alkoxycarbonyl(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, (1-6C)alkylamino, di-\x9b(1-6C)alkyl!amino, carbamoyl, (1-6C) alkylcarbamoyl, di-\x9b(1-6C)alkyl!carbamoyl, (1-6C)alkenyl and oxime derivatives thereof and O--(1-6C)alkyl ethers of said oximes (1-6C)alkylthio, (1-6C)alkylsulphinyl and (1-6C)alkylsulphonyl when substituted by one or more groups selected from (1-6C)alkoxycarbonyl, (1-6C)alkanoyl and oxime derivatives thereof and O-(1-6C)alkyl ethers of said oxime derivatives, (1-6C)alkanoylamimo, (1-6C)alkanoyloxy, (1-6C)alkanoyloxy(1-6)alkyl, carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di\x9b(1-6C)alkyl!carbamoyl, amino, (1-6C)alkylamino, di-\x9b(1-6C)alkyl!amino, (1-6C)alkoxy, (2-6C)alkenyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, halogeno(1-6C)alkyl (2-6C)alkenyl, (2-6C)alkynyl, phenyl, phenoxy, cyano, nitro, hydroxy and carboxy; and wherein Ar may bear further substituents; and their pharmaceutically acceptable salts inhibit squalene synthese and are hence useful in lowering cholesterol levels in blood plasma Processes for preparing compounds of formula (I) are also referred to as well as pharmaceutical compositions containing them and their use in medicine.

  式(I)中的化合物，其中R.sup.1是氢或羟基；R.sup.2是氢；或R.sup.1和R.sup.2结合在一起，使得CR.sup.1 14 CR.sup.2是一个双键；X从--Ch.sub.2 CH.sub.2 --，--C.dbd.CH--，--C.tbd.C--，--CH.sub.2 O--，--OCH.sub.2，CH.sub.2 NH--，--NHCH.sub.2 --，--CH.sub.2 CO--，--COCH.sub.2 --，--CH.sub.2 S(O).sub.n --和--S(O).sub.n CH.sub.2 --中选择（其中n为0、1或2）；Ar是苯基，其上独立选择自基团（1-6C）烷基，（2-6C）烯基，（2-6C）炔基，（1-6C）烷氧基，（1-6C）烷氧羰基，（1-6C）烷氧羰基（1-6C）烷基，（1-6C）烷氧基（1-6C）烷基，（1-6C）烷基氨基，二-\x9b（1-6C）烷基！氨基，氨基甲酰基，（1-6C）烷基甲酰基，二-\x9b（1-6C）烷基！甲酰基，（1-6C）烯基和其氧肟衍生物和所述氧肟的O-（1-6C）烷基醚（1-6C）烷硫基，（1-6C）烷磺基和（1-6C）烷磺基，当被一个或多个基团选择时，从（1-6C）烷氧羰基，（1-6C）烷酰基和其氧肟衍生物和所述氧肟衍生物的O-（1-6C）烷基醚，（1-6C）烷酰胺基，（1-6C）烷酰氧基，（1-6C）烷酰氧基（1-6）烷基，氨基甲酰基，N-（1-6C）烷基甲酰基，N，N-二\x9b（1-6C）烷基！甲酰基，氨基，（1-6C）烷基氨基，二-\x9b（1-6C）烷基！氨基，（1-6C）烷氧基，（2-6C）烯氧基，（1-6C）烷硫基，（1-6C）烷磺基，（1-6C）烷磺基，卤代（1-6C）烷基（2-6C）烯基，（2-6C）炔基，苯基，苯氧基，氰基，硝基，羟基和羧基；其中Ar可能带有进一步的取代基；它们的药学上可接受的盐抑制角鲨烯合成，因此在降低血浆胆固醇水平方面有用。制备式(I)化合物的方法也被提及，以及含有它们的药物组合物及其在医学中的用途。
• Therapeutic amines
  申请人：Zeneca Limited

  公开号：US05866611A1

  公开（公告）日：1999-02-02

  Compounds of formula I, and their pharmaceutically acceptable salts, ##STR1## in which R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl or alkenyl; or NR.sup.1 R.sup.2 is a heterocyclic group; A is trimethylene optionally substituted by alkyl and the phenyl ring is optionally substituted by substituents such as halogeno, alkenyl, amino, cyano, ureido, alkyl, carbamoylalkyl, alkanoylamino, alkoxycarbonyl, N-alkyl-alkanoylamino, alkanoyl and amines thereof; are inhibitors of squalene synthese and hence useful in treating diseases in which a lowering of cholesterol is desirable. As well as the use of these compounds in medicine, novel compounds, processes for their preparation and pharmaceutical compositions are also referred to.

  式I的化合物及其药学上可接受的盐，其中R.sup.1和R.sup.2分别为氢、烷基、环烷基、环烷基烷基、苯基烷基或烯基；或NR.sup.1 R.sup.2是杂环基团；A是可选择地由烷基取代的三亚甲基，苯环可选择地由卤素、烯基、氨基、氰基、脲基、烷基、碳酰胺基烷基、烷酰氨基、烷氧羰基、N-烷基-烷酰氨基、烷酰基及其胺基取代基取代；这些化合物是角鲨烯合成酶的抑制剂，因此在治疗降低胆固醇的疾病中有用。除了这些化合物在医学上的用途外，还提到了新颖的化合物、其制备方法和药物组合物。